Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial
According to this pilot trial, Tenofovir Alafenamide Fumarate, along with conventional treatment, significantly reduced mechanical ventilation and ICU stay in COVID-19 patients. Further thorough research is necessary to verify this conclusion.
Authors
- Niloofar Neisi (ORCID: https://orcid.org/0000-0001-8224-4890)
- Ali Akbar Shayesteh (ORCID: https://orcid.org/0000-0002-7636-1369)
- Afshin Talebi
- Fatemeh Ahmadi (ORCID: https://orcid.org/0000-0002-7021-6881)
- Zahra Shokati Eshkiki (ORCID: https://orcid.org/0000-0002-9478-4840)
- Bahman Cheraghian
- Nazanin Yazdan Pouri
Institutions
- Ahvaz Jundishapur University of Medical Sciences (IR)
- Imam Khomeini Hospital (IR)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1186/s40360-024-00781-3
- Citations
- 1
- Primary Topic
- Infectious Encephalopathies and Encephalitis
- Type
- article
- Field-Weighted Citation Impact
- 0.39